Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Tasly Pharmaceutical Group Co., Ltd.

Tianjin Tasly Group Co., Ltd.

Tianjin Kinsly Pharmaceutical Co. Ltd.

Guocheng Wang

Qingwei Hou

Wenzheng Liu

Yongfeng Wang

Wei Zhou

Huimin Wu

Hongguang Meng

Xueyu Xu

Jun Zhong

Yuzhe Gao

Yunrong Jing

Xiaohui Ma

Yonghong Zhu

Yu Xuan Zhang

Shuiping Zhou

Jianming Chen

Min Han

Lanlan Zhang

Lulu Yan

Yuanpeng Jin

Yu Zhang

Wangyi Zhou

Xuejun Luo

Weiwei Ma

Guojun Yang

Qiaoping Cui

Zhanyuan Zhu

Jinping Liu

Mingbo Yang

Hailong Yang

Xinbo Lu

Qinxuan Liu

Yu Tang

Liping Yang

Qinqin Zhou

Wenli Liu

Bao'an Gao

The present invention relates to a novel FXR agonist having a pyrazine structure, a preparation method therefor and the use thereof, and in particular relates to a compound as represented by the following general formula (I), or a hydrate, a solvate or a pharmaceutically acceptable salt thereof or a resolved single isomer thereof, which has the effect of treating non-alcoholic fatty liver disease.

FXR agonist having pyrazine structure, and preparation method and use

The present invention relates to a S-substituted-2-amino-3-mercaptopropionate derivative, a preparation method and an application thereof. The S-substituted-2-amino-3-mercaptopropionate derivative in the present invention has a structure of a formula (A). The present invention also includes an application of the S-substituted-2-amino-3-mercaptopropionate derivative serving as a medicine for treating and/or preventing neurodegenerative diseases, particularly Alzheimer's disease. 

S-substituted-2-amino-3-mercaptopropionate derivative, preparation method and application thereof

The present invention discloses deuterated thienopiperidine derivatives, a manufacturing method and an application thereof. The deuterated thienopiperidine derivatives in the present invention are of a structure of the following formula (I). The present invention also comprises the application of the deuterated thienopiperidine derivatives as a drug for treating and preventing cardiovascular and cerebrovascular diseases. 

Deuterated thienopiperidine derivatives, manufacturing method, and application thereof

The present invention relates to a uridine phosphoramide prodrug, the preparation method therefor, and the medicinal uses thereof. The prodrug of the present invention is a chemical compound as shown in formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The prodrug of the present invention further comprises a solvate of the chemical compound shown in formula I, of an optical isomer thereof or of a pharmaceutically acceptable salt thereof. The prodrug of the present invention can treat viral infectious diseases, particularly hepatitis C viral infectious diseases. 

Uridine phosphoramide prodrug, preparation method therefor, and medicinal uses thereof

The present invention relates to a Xanthine derivative as shown in formula (I), wherein, 

Xanthine derivative

The present invention provides taxanes compounds with a formula (I) or formula (II) structure, a method for preparing the compounds, as well as the use of the compositions containing the compounds, pharmaceutically acceptable salts and solvates thereof as active ingredients in manufacturing oral antitumor medicaments,  In formula (I), Ris &#x2014;COR, &#x2014;COORor &#x2014;CONRR; Ris a C1-C6 alkyl, a C1-C6 alkenyl, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSRor &#x2014;OCONRR; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSR, &#x2014;OCONRRor H; wherein, Ris a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; Rand Rare respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group. In formula (II), Ris &#x2014;CORor &#x2014;COOR; Ris an aromatic group; Ris &#x2014;OR; wherein, Ris a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group.

Taxanes compounds, preparation method therefor, and uses thereof

The present invention relates to a tenofovir monobenzyl ester phosphamide prodrug, preparation method and pharmaceutical use thereof. Specifically, the present invention relates to a compound of general formula (X), or isomer, pharmaceutically-acceptable salt, hydrate or solvate thereof, preparation method and use thereof in the preparation of drugs for treating viral infectious diseases, preferably AIDS infection, hepatitis B or diseases caused by hepatitis B virus. 

Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof

The present invention relates to substituted cinnamamide derivatives, the method for preparing thereof and the use thereof. Each of said derivatives has a structure of formula (I). The method for preparing the substituted cinnamamides and their derivatives of the present invention is also disclosed. Substituted piperonal derivatives are selected as starting materials to prepare the substituted cinnamamide derivatives of the present invention by Wittig reaction and acid-amine condensation reaction. Further, a use of the present compounds in preventing and treating depressive-type mental diseases is disclosed. 

Substituted cinnamamide derivative, preparation method and use thereof

Provided are revaprazan hydrochloride polymorphs and a preparation method thereof. The method comprises a step of dissolving revaprazan hydrochloride in ethanol or aqueous solutions of ethanol having different proportions to perform recrystallization.

Revaprazan hydrochloride polymorphs and preparation method therefor

Provided is a preparation method for revaprazan hydrochloride, the method comprising: (1) the preparation of 4-hydroxyl-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (2) the preparation of 4-chloro-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (3) the preparation of revaprazan hydrochloride. The method has advantages such as simple operations, high product purity, good yield and suitability for industrial production.

Preparation method for revaprazan hydrochloride

Provided are taxanes compounds having the structure of formula I, preparation method thereof, and uses of compositions having the compound, pharmaceutical salts and solvates thereof as active ingredients in the preparation of oral antitumor drugs. In the formula, Ris &#x2014;COR, &#x2014;COOR, and &#x2014;CONRR; Ris C1-C6 alkyl, C1-C6 alkenyl group, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSR, and &#x2014;OCONRR; Ris &#x2014;OR, &#x2014;OCOOR, &#x2014;OCOSR, &#x2014;OCONRR, H, and OH; Ris C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl group, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; and Rand Rare respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group. 

Taxane compound, and preparation method and use thereof

Provided in the present invention are a new method for preparing the crystalline forms of Temozolomide and three types of crystalline form of Temozolomide by the method. Said method comprises the following steps: a Temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester.

Crystalline forms of temozolomide and the method for preparing same

The present invention discloses a crystalline form of S-zopiclone (Formula I) having a powder X-Ray diffraction spectrum excited by Cu-Ka radiation with characteristic peaks expressed in terms of 2&#x3b8; at about 11.08&#xb0;, about 12.38&#xb0;, about 15.86&#xb0;, about 17.88&#xb0;, about 19. 98&#xb0; and about 20.58&#xb0;; a DSC thermogram with a peak at about 207.7&#xb0; C. and an infrared absorption spectrum (IR) with characteristic peaks at about 3078 cm, about 2942&#x2dc;2838 cm, about 2790 cm, about 1716 cm, about 1463 cm, about 1372 cmand about 757 cm. The present invention also discloses a method for preparing the crystalline form of eszopiclone, its pharmaceutical composition and its use in preparing a medicament for treating sleep disorders. 

Crystalline form of eszopiclone, composition, preparation and uses thereof

A new crystal form of adefovir dipivoxil {9-[2-[bis(pivaloyloxy)-methoxy]-phosphinyl]-methoxyl]-ethyl]-adenime} and its composition is disclosed, as is a method to prepare the crystal comprising placing adefovir dipivoxil in a round bottom flask, adding organic solvent and dissolivng adefovir dipivoxil ultrasonically to form and adefovir dipivoxil solution, and spray drying the adefovir dipivoxil solution.

Growing community of inventors

Tianjin, China

Guocheng Wang